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INTRODUCTION
South Korea is presently experiencing rapid economic, social, 
and cultural changes, including an accelerated pace of nutri-
tion transition that may result in a greatly increased burden of 
chronic diseases, such as obesity.1 Obesity causes many serious 
medical illnesses that impair the quality of life and often leads 
to increased morbidity and mortality.2 Many prospective stud-
ies have shown that visceral fat leads to insulin resistance and is 
associated closely with hypertension and dyslipidemia, which 
enhance atherosclerosis.3-5 Subjects with type 2 diabetes melli-
tus (T2DM) are especially at high risk for cardiovascular diseas-
es (CVD) and visceral obesity. Therefore, early and proper esti-
mates of visceral adiposity and atherosclerotic disease risks are 
very important in T2DM subjects.
Chemerin, a recently discovered adipocytokine, is hypothe-
sized to be associated with glucose and lipid metabolism, obe-
sity-induced insulin resistance and metabolic complications.6-8 
In addition, serum chemerin levels reportedly correlate with 
body mass index (BMI), waist circumference (WC) and amount 
of visceral fat in the general population.6,9,10 Currently, a positive 
correlation has been shown between abdominal visceral fat 
and serum chemerin levels in type 2 diabetic subjects with the 
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average six years of duration.11 However, the relationship be-
tween serum chemerin levels and visceral fat amount in sub-
jects with newly diagnosed type 2 diabetes has not yet been 
well studied, and this relationship may be different from those 
under medication. Therefore, we determined whether serum 
chemerin levels are associated with visceral adiposity in newly 
diagnosed T2DM subjects in South Korea.
MATERIALS AND METHODS
Study subjects
Among the patients who visited the outpatient department of 
Endocrinology and Metabolism at Hallym University Sacred 
Heart Hospital from March 2009 to May 2010, 102 newly diag-
nosed, consecutive T2DM subjects were enrolled in this study. 
The exclusion criteria were type 1 diabetes, history of clinical 
coronary artery disease or cerebral or peripheral vascular dis-
ease, renal dysfunction (defined as a creatinine level ≥2 mg/
dL), hepatic dysfunction (defined as alanine aminotransferase 
and/or aspartate aminotransferase blood levels ≥ 3-fold the up-
per normal limit), use of glucocorticoids, pregnancy, severe 
diseases such as cancer, infection, Cushing’s syndrome, acro-
megaly or any other disorder likely to alter glycemia, primary 
hypercholesterolemia, hypothyroidism or hyperthyroidism, use 
of any hormonal medications, alcoholism or drug abuse. Hy-
pertension was defined as a systolic blood pressure of at least 
140 mm Hg and/or a diastolic blood pressure of at least 90 mm 
Hg, use of antihypertensive drugs, or a combination of these 
parameters. Dyslipidemia was defined as a low-density lipo-
protein cholesterol (LDL-C) level ≥100 mg/dL or a high-density 
lipoprotein cholesterol (HDL-C) level <40 mg/dL for males or 
<50 mg/dL for females or the use of lipid-lowering drugs. The 
protocol was approved by the Ethics Committee of the Hallym 
University Sacred Heart Hospital, and informed written con-
sent was obtained from each subject.
Anthropometric, blood pressure and biochemical 
measurements
Height and weight were measured in each subject wearing light 
clothing and without shoes. WC was determined at the mid-
point between the lower ribs and the iliac crest. BMI was calcu-
lated by dividing weight by height squared (kg/m2). Blood sam-
ples were collected from subjects after more than 10 h of fasting. 
HbA1c was determined using high-performance liquid chro-
matography (Variant II; Bio-Rad, Hercules, CA, USA). Plasma 
glucose levels were measured immediately after sampling us-
ing an auto-analyzer and the hexokinase method (Hitachi 747; 
Roche, Montclair, NJ, USA). Serum insulin levels were deter-
mined using the INS-IRMA Kit (BioSource Europe S.A., Nev-
elles, Belgium), and serum total cholesterol and HDL-C were 
measured using a direct enzymatic method (Hitachi 747; Dai-
ichi, Tokyo, Japan). Serum triglyceride levels were measured 
using an enzymatic colorimetric method (Hitachi 747; Roche, 
Tokyo, Japan/Mannheim, Germany), and LDL-C was calculat-
ed using the Friedewald formula. Insulin resistance was esti-
mated after fasting using the homeostasis model assessment of 
insulin resistance (HOMA-IR): HOMA-IR=fasting insulin (μU/
mL)×fasting plasma glucose (mmol/L)/22.5. High-sensitivity C-
reactive protein (hs-CRP) was measured using a latex-en-
hanced immunoturbidimetric method (TBA-120FR, Toshiba, 
Tokyo, Japan). Chemerin levels were measured using an en-
zyme immunoassay kit (Mesdia, Seoul, Korea) with intra-assay 
and inter-assay coefficients of 8.5% and 7.4% variance, respec-
tively.
Visceral fat thickness (VFT)
To assess visceral adiposity, ultrasonography (US) was per-
formed using a 3.5-MHz convex probe (LOGIQ 7, GE, Milwau-
kee, WI, USA) with the subjects in the supine position. The pro-
cedures were conducted after subjects fasted at least 4 h. To 
measure visceral fat thickness (VFT), transverse scanning was 
performed 1 cm above the umbilicus. The probe was placed as 
lightly as possible to the skin to avoid disfiguring the abdominal 
cavity. Images were collected immediately after expiration to 
reduce the influence of the respiration. VFT was defined as the 
distance between the anterior aortic wall and the internal face 
of the rectus abdominis muscle vertical to the aorta. Intra-ob-
servational coefficient of variation was 1.5–2.0%.
Statistics
Continuous variables were reported as means±standard devia-
tion. Independent t-tests and chi-square tests were used for 
comparisons between males and females where appropriate. 
The relationships between serum chemerin levels and clinical 
and biochemical parameters were examined using the Pearson 
correlation and partial correlation analyses. Three models exam-
ining the association between serum chemerin levels and clini-
cal and biochemical parameters were used under different ad-
justment schemes. Inclusion of adjustments in the partial 
correlation analyses removed their possible contribution to se-
rum chemerin levels. The first model was adjusted for age and 
gender. The second model was adjusted for BMI in addition to 
age and gender, and the third model was adjusted for WC in 
addition to age, gender, and BMI. To determine the predictable 
factors of the serum chemerin levels, a multiple linear regres-
sion analysis was performed. We selected all of the variables 
which showed a potential association (p<0.20) with serum 
chemerin levels in the Pearson’s correlation analysis. According 
to previous studies, we additionally entered blood pressure val-
ues related to serum chemerin levels.6,8,10 Variables that were 
not normally distributed, such as triglycerides and hs-CRP, 
were log transformed to better approximate normal distribu-
tions. We calculated the sample size for α=0.05 and a global 
power 1-β=0.8. The minimal sample size required was 56 for 
the Pearson’s correlation coefficient (r)=0.37, which derived 
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from previous research.10 The PASW version 18.0 software (IBM 
Co., Armonk, NY, USA) was used for the statistical analyses. A p-
value <0.05 was considered to indicate statistical significance.
RESULTS
Clinical and biochemical characteristics 
of the subjects
Table 1 shows the clinical characteristics of the 102 study sub-
jects [49 females (48.0%) and 53 males (52.0%)], with an aver-
age age of approximately 50 years for both genders. BMI (25.4 
kg/m2 in females; 25.8 kg/m2 in males) and WC (87.8 cm in fe-
males; 92.9 cm in males) were slightly over the reported obesity 
diagnostic criteria for South Koreans.12,13 The proportions of ac-
tive smokers were 12.2% in females and 28.3% in males. WC, 
VFT and creatinine levels were significantly higher in males than 
females. However, no significant differences were observed in 
age, BMI, blood pressures, insulin, C-peptide, HOMA-IR, HbA1c, 
fasting and postprandial glucose, cholesterol profiles, hs-CRP 
(log-transformed), blood urea nitrogen and chemerin levels 
between females and males.
Relationships between serum chemerin levels 
and clinical and biochemical parameters
Serum chemerin levels showed significant positive correlations 
with BMI, WC, VFT, fasting insulin levels, HOMA-IR, and levels 
of triglycerides (log-transformed) and hs-CRP, while showing 
significant negative correlations with HDL-C (Fig. 1). After ad-
justing for age and gender, serum chemerin levels showed sig-
Table 1. Clinical Characteristics of the Subjects
Female Male p value
Number of subjects 49 53
Age (yr) 49.4±11.3 48.4±9.1 0.622 
Hypertension (%) 42.9 45.3 0.805
Antihypertensive treatment (%)
ACEi 2.0 1.9 0.955
ARB 32.7 34.0 0.889
CCB 12.2 13.2 0.884
Dyslipidemia (%) 59.2 64.2 0.606
Lipid-lowering treatment (%)
Statins 42.9 43.4 0.956
Active smoker (%) 12.2 28.3 0.045
BMI (kg/m2) 25.4±3.7 25.8±3.4 0.554
WC (cm) 87.8±8.9 92.9±9.2 0.008 
VFT (cm) 3.9±1.2 4.6±1.4 0.005
SBP (mm Hg) 128.0±15.3 127.0±16.8 0.760
DBP (mm Hg) 77.1±10.6 80.2±9.9 0.141
Fasting insulin (pmol/L) 59.6±33.7 55.3±37.3 0.638
Fasting C-peptide (pmol/L) 0.73±0.3 0.86±0.5 0.152
HOMA-IR 3.4±3.7 2.9±1.9 0.480
HbA1c (%; mmol/mol) 7.6±1.6 (60±17.5) 7.9±1.9 (63±20.8) 0.403
Fasting blood glucose (mmol/L) 7.6±2.4 8.5±3.1 0.145
PP2hr blood glucose (mmol/L) 10.2±3.7 11.8±5.0 0.086
Total cholesterol (mmol/L) 4.6±0.9 4.8±1.0 0.293
Log_triglyceride (mg/dL) 4.8±0.5 4.9±0.6 0.271
HDL-C (mmol/L) 1.3±0.3 1.2±0.3 0.124
LDL-C (mmol/L) 2.7±0.8 2.8±0.8 0.453
Log_hs-CRP (mg/L)  0.12±1.07 -0.13±1.06 0.603
BUN (mmol/L) 5.2±1.6 5.5±1.6 0.408
Creatinine (μmol/L) 62.1±8.9 79.8±8.9 <0.001
Chemerin (μg/L) 45.0±19.8 40.0±15.3 0.157
ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; BMI, body mass index; WC, waist circumfer-
ence; VFT, visceral fat thickness; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, homeostatic model assessment of insulin resistance; 
PP2hr, postprandial 2 hour; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hs-CRP, high-sensitivity C-reactive protein; 
BUN, blood urea nitrogen.
Data represent means±standard deviations, unless otherwise noted. 
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nificant positive correlations with BMI, WC, VFT, levels of tri-
glyceride (log-transformed) and hs-CRP, while showing 
significant negative correlations with HDL-C. After adjusting 
for age, gender and BMI, only VFT showed a significant rela-
tionship to serum chemerin levels. Although weakened after 
additionally adjusting for WC, this relationship remained statis-
tically significant (Table 2).
Multiple linear regression analysis for predictors 
of serum chemerin levels
Multiple linear regression analysis was performed to evaluate 
factors that influence serum chemerin levels. Only VFT was an 
independent predictive factor for serum chemerin levels 
(β=0.242, p= 0.041) (Table 3), while BMI, WC, and metabolic 
syndrome components were not.
DISCUSSION
In the present study, we demonstrated that serum chemerin lev-
els were significantly associated with obesity, especially visceral 
adipose tissue, in newly diagnosed T2DM subjects. Moreover, af-
ter adjusting for BMI and WC, VFT had a significant relationship 
with serum chemerin levels and was the only determinant.
Our results are consistent with previous studies reporting 
that chemerin is significantly associated with BMI, WC, and 
various metabolic syndrome components.6,9,10 Moreover, in a 
study conducted in the group without diabetes, chemerin levels 
were correlated positively with the amount of abdominal vis-
ceral fat.10 In the study by Weigert, et al.,14 chemerin was elevat-
ed in T2DM subjects with higher CRP levels (>5 ng/mL) and 
positively correlated with CRP in normal weight, overweight 
and T2DM subjects after adjusting for BMI and WC. The au-
thors proposed that systemic chemerin levels are related to in-
flammation rather than obesity in T2DM subjects. However, 
there are some differences between Weigert’s study and our 
study. Firstly, only about 40% (n=44) were T2DM subjects in 
their study. In addition, the subjects in their study exhibited 
several clinical characteristics different from our study subjects 
including the following: T2DM for an average of 5 years versus 
our newly diagnosed subjects; a mean age approximately 10 
years greater than that of our subjects; and very high CRP level 
(4.0 mg/L) in their T2DM subjects versus a mean level of 1.59 
mg/L and a moderate state in our study.15 Chemerin was asso-
ciated with the amount of visceral fat after adjusting for age, 
gender and BMI in the general population, suggesting visceral 
fat as the major site for chemerin secretion.10 Specifically, in our 
study, visceral fat had a significant positive correlation with se-
rum chemerin levels after adjusting for WC, indicating that 
chemerin levels are dependent on visceral fat rather than sub-
cutaneous fat in T2DM subjects, similar to the subjects without 
diabetes.10
Table 2. Relationship between Serum Chemerin Levels and Clinical Parameters 
Pearson’s correlation Age, gender adjusted Age, gender, BMI adjusted Age, gender, BMI, WC adjusted
r p value r p value r p value r p value
Age (yr) -0.028 0.782
Gender (female=0) -0.176 0.077
BMI (kg/m2) 0.343 <0.001 0.539 <0.001
WC (cm) 0.360 <0.001 0.405 0.004 0.129 0.202
VFT (cm) 0.390 <0.001 0.573 <0.001 0.252 0.011 0.222 0.027
SBP (mm Hg) 0.101 0.316 0.142 0.337 -0.067 0.653 -0.061 0.687
DBP (mm Hg) 0.105 0.295 0.154 0.295 -0.012 0.937 0.002 0.987
Fasting insulin (pmol/L) 0.452 <0.001 0.211 0.150 -0.021 0.891 -0.080 0.599
Fasting C-peptide (pmol/L) 0.154 0.136 0.278 0.056 0.081 0.590 0.048 0.751
HOMA-IR 0.429 <0.001 0.191 0.194 -0.017 0.911 -0.083 0.582
HbA1c (%) 0.041 0.683 0.176 0.089 0.153 0.303 0.119 0.432
Fasting blood glucose (mmol/L) 0.001 0.993 0.033 0.826 0.065 0.663 0.042 0.780
PP2hr blood glucose (mmol/L) 0.037 0.715 0.064 0.665 0.102 0.495 0.081 0.592
Total cholesterol (mmol/L) -0.100 0.319 -0.005 0.974 0.013 0.928 -0.016 0.917
Log_Triglyceride (mg/dL) 0.282 0.004 0.420 0.003 0.245 0.098 0.204 0.174
HDL-C (mmol/L) -0.318 0.002 -0.357 0.013 -0.179 0.229 -0.166 0.269
LDL-C (mmol/L) -0.145 0.148 -0.056 0.704 -0.017 0.911 -0.019 0.900
Log_hs-CRP (mg/L)  0.263 0.037 0.354 0.014 0.087 0.560 0.055 0.715
BUN (mmol/L) -0.039 0.697 -0.039 0.791 0.130 0.385 0.168 0.264
Creatinine (μmol/L) -0.004 0.971 0.201 0.170 0.198 0.183 0.194 0.197
BMI, body mass index; WC, waist circumference; VFT, visceral fat thickness; SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, homeostatic 
model assessment of insulin resistance; PP2hr, postprandial 2 hour; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hs-
CRP, high-sensitivity C-reactive protein; BUN, blood urea nitrogen.
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Recently, Han, et al.11 suggested that serum chemerin levels 
are significantly associated with the amount of abdominal vis-
ceral fat in Korean subjects with T2DM. However, our study ex-
clusively included newly diagnosed T2DM subjects. Even 
though latent period before the diagnosis varied, we could rule 
out the possibility of medication effect because newly diag-
nosed T2DM patients were not taking anti-diabetic medica-
tions. Chemerin is one of the target gene for PPAR gamma and 
use of pioglitazone or metformin can decrease serum chemerin 
concentration16,17 Moreover, diabetes patients with nephropa-
thy show decreased ability of chemerin degradation, so that it 
might affect serum chemerin level, as well.18 In Han, et al.11 study, 
the study population had 6 years of average duration of diabe-
tes, the stage 2 chronic kidney disease state and higher albu-
min-creatinine ratio (45.1 μg/mg). In this regard, therefore, our 
study which was designed for newly diagnosed T2DM patients 
has enough novelty. Chemerin promotes chemotaxis of den-
dritic cells and macrophages to the site of inflammation, and its 
receptor is expressed by tissue macrophages.19 Moreover, se-
rum chemerin levels correlate with the levels of proinflamma-
tory cytokines such as tumor necrosis factor-α, interleukin-6 
and CRP.20 These observations suggest that chemerin may play 
a role in the development of inflammatory diseases. In our 
study, serum chemerin levels correlated positively with hs-CRP, 
a circulating marker of inflammation.
Many human data support a relationship between chemerin, 
obesity and metabolic syndrome.21 In the present study, we 
found that serum chemerin levels were significantly associated 
with several key components of metabolic syndrome. These 
findings suggest that chemerin plays a role in metabolic syn-
drome and is an independent adipokine marker of metabolic 
syndrome.22
Although not statistically significant, many researchers have 
reported a positive relationship between chemerin and blood 
pressure.10,23-25 However, several studies have been carried out 
on the relationship between blood pressure and chemerin in 
T2DM subjects: weak positive correlations between blood pres-
sure and chemerin in T2DM subjects with hypertension, renal 
dysfunction and coronary artery disease.8,18,26 The effect of 
chemerin on blood pressure may be related to its high expres-
sion levels in the kidneys and kininogen, a proteolytic product 
of the vasoactive peptide bradykinin; however, the exact mech-
anism is unclear.15 In our study, there was no significant rela-
tionship between blood pressure and serum chemerin levels. 
This discrepancy may be due to the differences in study popu-
lations; for example, the subjects who participated in our study 
had lower cardiovascular risks than those in other studies.
It should be mentioned that VFT measurement using US may 
not necessarily be accurate for measuring visceral fat in some 
selected groups.27,28 Usually, abdominal computed tomography 
(CT) or magnetic resonance imaging (MRI) are considered the 
gold standard methods for the assessment of visceral fat.29 How-
ever, radiation exposure for CT and cost-effectiveness for MRI 
are limitations of those methods. Instead, US is an accurate, 
cost-effective, noninvasive and reproducible method to mea-
sure the accumulation of visceral fat.30 The amount measured of 
visceral fat by US is closely related to an increased risk of CVD.31 
Table 3. Multiple Regression Analysis of Serum Chemerin Levels
 β p value
Gender (female=0) -0.172 0.300
BMI (kg/m2) 0.204 0.108
WC (cm) 0.195 0.138
VFT (cm) 0.242 0.041
SBP (mm Hg) -0.077 0.737
DBP (mm Hg) 0.043 0.858
Fasting insulin (pmol/L) 0.018 0.924
Fasting C-peptide (pmol/L) -0.176 0.632
HOMA-IR 0.211 0.391
Log_triglyceride (mg/dL) 0.151 0.307
HDL-C (mmol/L) -0.006 0.975
LDL-C (mmol/L) -0.112 0.423
Log_hs-CRP (mg/L)  0.004 0.981
BMI, body mass index; WC, waist circumference; VFT, visceral fat thickness; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; HOMA-IR, ho-
meostatic model assessment of insulin resistance; HDL-C, high-density lipo-
protein cholesterol; LDL-C, low-density lipoprotein cholesterol; hs-CRP, high-
sensitivity C-reactive protein.
Fig. 1. (A) Relationship between serum chemerin levels and body mass index. (B) Relationship between serum chemerin levels and waist circumference. 
(C) Relationship between serum chemerin levels and visceral fat thickness.
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Moreover, the amount measured by using US has been report-
ed to have a similar accuracy compared to CT.32
There was no association between the amount of subcutane-
ous fat and chemerin concentrations in a previous study.10 In 
our study, we did not check subcutaneous fat amount. Our 
small sample size is an another limitation of our study. The 
cross-sectional nature of our study limited the determination of 
cause-effect relationships, and therefore, additional longitudinal 
studies with larger sample sizes are necessary to confirm our 
findings. Despite several limitations, our study provides impor-
tant novel data regarding the relationship between chemerin 
and visceral adiposity in subjects newly diagnosed with T2DM.
In conclusion, abdominal visceral fat was identified as an in-
dependent predictor of serum chemerin levels in subjects newly 
diagnosed with T2DM. Our findings suggest that chemerin may 
be a mediator linking visceral obesity and T2DM.
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